









Markets
/
Stocks
/
nasdaq-jspr
/

Jasper Therapeutics Inc

JSPR

1.950USD

+0.140+7.73%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

31.63MMarket Cap

LossP/E TTM



Jasper Therapeutics Inc

1.950

+0.140+7.73%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Jasper Therapeutics Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Jasper Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

279 / 501

Overall Ranking

503 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

12.833

Target Price

+609.02%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Jasper Therapeutics Inc Highlights

StrengthsRisks

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -0.39, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 13.96M shares, decreasing 33.06% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 624.60K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.64.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Jasper Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.36, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -0.39, which is -72.15% below the recent high of -0.11 and -2804.26% above the recent low of -11.19.

Score

Industry at a Glance

Previous score

6.36

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 279/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 7.56, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Jasper Therapeutics Inc is 10.50, with a high of 25.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

7.56

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

12.833

Target Price

+609.02%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Jasper Therapeutics Inc

JSPR

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 4.01, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 2.59 and the support level at 2.17, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.36

Change

-0.35

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.095

Sell

RSI(14)

34.971

Neutral

STOCH(KDJ)(9,3,3)

14.410

Oversold

ATR(14)

0.180

High Vlolatility

CCI(14)

-174.329

Sell

Williams %R

83.146

Oversold

TRIX(12,20)

-0.543

Sell

StochRSI(14)

50.901

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.064

Sell

MA10

2.205

Sell

MA20

2.342

Sell

MA50

2.456

Sell

MA100

3.099

Sell

MA200

4.160

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 50.04%, representing a quarter-over-quarter decrease of 43.46%. The largest institutional shareholder is The Vanguard, holding a total of 624.60K shares, representing 2.24% of shares outstanding, with 52.65% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Velan Capital Investment Management LP

2.67M

+86.10%

Soleus Capital Management, L.P.

1.49M

Abingworth Management Limited

1.07M

Qiming U.S. Ventures Management, LLC

928.96K

Kingdon Capital Management, L.L.C.

765.00K

+11.73%

Morgan Stanley & Co. LLC

758.02K

+18.32%

T. Rowe Price Investment Management, Inc.

703.65K

+0.13%

The Vanguard Group, Inc.

Star Investors

624.60K

-8.07%

Integral Health Asset Management, LLC

590.00K

+2.61%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 2.84. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.